ERBB2 and breast cancer: We retrospectively evaluated a cohort of HR+/HER2– early BC patients treated at a single institution who underwent Oncotype DX for risk definition and adjuvant treatment decision-making, looking for pathological features correlated to RS in the overall population and in the pre- and post-menopausal subgroups.